$26.20
1.58%
NYSE, Nov 19, 04:00 pm EST. Closed.
ISIN
US03237H1014
Symbol
AMLX

Amylyx Pharmaceuticals Stock price

$26.20
-1.13 4.13% 1M
+13.46 105.65% 6M
+14.12 116.89% YTD
+11.88 82.96% 1Y
+13.29 102.94% 3Y
+8.13 44.99% 5Y
+8.13 44.99% 10Y
+8.13 44.99% 20Y
NYSE, Closing price Thu, Nov 19 2026
-0.42 1.58%
ISIN
US03237H1014
Symbol
AMLX
Industry

Is Amylyx Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$3.4b
Enterprise Value
$3.1b
Net debt
positive
Cash
$250.8m
Shares outstanding
111.4m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
14.1
Financial Health
Equity Ratio
91.8%
Return on Equity
-47.4%
ROCE
-66.6%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$27.9m | -
SBC as % of FCF
-
SBC Growth 1Y
0.6%
Share Count Growth 1Y
24.9%
Shareholder Yield
-24.9%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-161.7m
EBIT
$-162.1m
Net Income
$-152.1m
Free Cash Flow | ex SBC
$-126.7m | $-154.6m
Growth
Revenue | estimate
-100.0% | -
EBITDA
-1.0%
EBIT
-0.8%
Net Income
18.9%
Free Cash Flow
37.2%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-1.4
FCF per Share
$-1.1
Short interest
12.4%
Employees
136
Rev per Employee
$0.0

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Amylyx Pharmaceuticals forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy
89%
Hold
11%

Amylyx Pharmaceuticals Events

Past Events
NOV
15
Special Call - Amylyx Pharmaceuticals, Inc.
5 days ago
NOV
5
Q3 2026 Earnings Call
15 days ago
SEP
15
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
AUG
18
Special Call - Amylyx Pharmaceuticals, Inc.
3 months ago
AUG
6
Q2 2026 Earnings Call
4 months ago
JUN
10
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
13
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
7
Q1 2026 Earnings Call
7 months ago
MAR
3
Q4 2025 Earnings Call
9 months ago
DEC
3
Citi Annual Global Healthcare Conference 2025
12 months ago
NOV
6
Q3 2025 Earnings Call
about one year ago

Financial data from Amylyx Pharmaceuticals

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 70 70
5% 5%
-
- Research and Development Expense 92 92
1% 1%
-
-162 -162
1% 1%
-
- Depreciation and Amortization 0.37 0.37
46% 46%
-
EBIT (Operating Income) EBIT -162 -162
1% 1%
-
Net Profit -152 -152
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Amylyx Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amylyx Pharmaceuticals Stock News

Neutral
Business Wire
●
5 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
Neutral
Business Wire
●
15 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.
More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Mr. Cohen
Employees 136
Founded 2013
Website www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today